Navigation Links
Human Genome Sciences Begins Delivery of First-in-Class Anthrax Treatment to U.S. Strategic National Stockpile
Date:2/2/2009

counter bioterrorism. These data are consistent with the results of previous studies in multiple animal models, which demonstrated that a single dose of raxibacumab given prophylactically provided up to 100% protection against death.

HGS has also completed safety studies of raxibacumab in more than 400 human volunteers. The clinical results to date suggest that raxibacumab was generally safe and well tolerated. In addition, clinical data have demonstrated that co-administration of raxibacumab with the antibiotic Cipro (ciprofloxacin) did not affect the pharmacokinetics of either Cipro or raxibacumab, and suggested that raxibacumab can be administered in combination with antibiotics. This is a key finding given the important role that antibiotics are expected to continue to play in the treatment of anthrax disease.

The Need for New Means to Fight Anthrax Infections

Two options have been available for the prevention or treatment of anthrax infections - a vaccine and antibiotics. Both are essential to dealing with anthrax, but both have limitations. The anthrax vaccine takes several weeks following the initial doses before immunity is detectable, and requires multiple injections over a period of eighteen months, in addition to annual booster vaccination, to maintain protective immunity. Antibiotics are effective in killing anthrax bacteria, but are not effective against the anthrax toxins once those toxins have been released into the blood. Antibiotics also may not be effective against antibiotic-resistant strains of anthrax.

ABthrax is a human monoclonal antibody to Bacillus anthracis protective antigen that was discovered and developed by HGS, using technology that HGS has integrated into the Company as part of its collaboration with Cambridge Antibody Technology. Research has shown that protective antigen is the key facilitator in the progression of anthrax infection at the c
'/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Mardil Inc. Advances Its Novel Cardiac Device to First-In-Human Trials for Mitral Valve Regurgitation
2. Modigene Announces Positive Results of Pilot Toxicity Study of Its Long-Acting Human Growth Hormone hGH-CTP
3. Human Genome Sciences Reports Substantial Progress Toward Commercialization and Announces 2009 Goals at JPMorgan Healthcare Conference
4. Cequent to Present First Proof of Activity of an Oral RNAi Drug in Non-Human Primates at February Keystone Conference
5. 2008 Human Research Protection Award Recipients Announced
6. USD 12.5 m Funding for the Development of Intercells Vaccine Patch System for Pandemic Influenza From U.S. Department of Health and Human Services (HHS)
7. Vical Pandemic Influenza Vaccines Achieve T-Cell Responses and Cross-Clade Reactivity in Humans
8. SARS Vaccine Achieves Neutralizing Responses in First U.S. Human Trial
9. GeoVaxs Phase 2a HIV/AIDS Vaccine Human Trials to Begin in North and South America
10. Celladon Announces Presentation of Clinical Data From First-in-Human MYDICAR(R) Trial for Advanced Heart Failure at American Heart Association Scientific Sessions
11. Micromet Presents Data at the 23rd Annual Meeting of the International Society for Biological Therapy of Cancer on the Activity of Human Antibody Adecatumumab against KRAS-mutated Colon Cancer Cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 2014 The Competitive Intelligence (CI) function is ... CI leaders who adjust will succeed, and those who ... Best Practices, LLC study CI leaders from 32 biopharmaceutical ... - Use secondary research whenever possible - it,s ... - Internal staff who are creative thinkers provide the ...
(Date:8/29/2014)... -- Pomerantz LLP has filed a class action lawsuit ... EDAP ) and certain of its officers.  The ... District of New York , and ... consisting of all persons or entities who purchased EDAP ... inclusive (the "Class Period"). This class action seeks to recover ...
(Date:8/29/2014)...   Mast Therapeutics, Inc. (NYSE MKT: ... Santosh Vetticaden, Chief Medical Officer and Senior Vice ... reasons, in mid-September.  Edwin L. Parsley , ... which Mast acquired earlier this year, will assume ... Chief Medical Officer.  Dr. Parsley previously was with ...
Breaking Medicine Technology:Using the Competitive Intelligence Function to Drive Better Business Decisions in the Pharmaceutical Sector 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against EDAP TMS S.A. and Certain Officers - EDAP 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against EDAP TMS S.A. and Certain Officers - EDAP 3Mast Therapeutics Announces Management Change 2Mast Therapeutics Announces Management Change 3Mast Therapeutics Announces Management Change 4
... announced the initiation of a landmark Phase 2 ... developed to improve neurological function in patients with ... In accordance with its internal focus on scientific ... at a peer-attended symposium at the American Spinal ...
... April 23, 2012 Medela convened the 7th ... on April 20-21, 2012. The annual event, attended ... lactation consultants, highlighted the latest insights into breastfeeding ... supporting breastfeeding women and their families through research ...
Cached Medicine Technology:Asubio Initiates Landmark Clinical Study in Spinal Cord Injury 2Asubio Initiates Landmark Clinical Study in Spinal Cord Injury 3Latest Findings in Breastfeeding Science Presented at Medela's 7th International Breastfeeding and Lactation Symposium 2Latest Findings in Breastfeeding Science Presented at Medela's 7th International Breastfeeding and Lactation Symposium 3
(Date:8/29/2014)... based on administering antidepressants for acute and chronic ... are needed to determine whether these drugs should ... basis., Dr. Ian Gilron, a professor and director ... Anesthesiology, and his team of seven researchers reviewed ... antidepressants for pain relief post-surgery would work more ...
(Date:8/29/2014)... Village, IL (PRWEB) August 29, 2014 ... in hearing wellness solutions, is on its way to ... at the San Diego Convention Center to exhibit and ... who work in high-noise industrial environments. Etymotic’s safety earphones ... hottest wearable technology devices at the show. , ...
(Date:8/29/2014)... IL (PRWEB) August 29, 2014 ... “The Safety Chick” who profiled a handful of ... Earphones from Etymotic Research. This year, many schools ... and Etymotic, an innovator of hearing wellness solutions, ... Their ETY•Kids Safe-Listening Earphones, offered in yellow, pink ...
(Date:8/29/2014)... London, UK (PRWEB) August 29, 2014 ... growing ones in the in-vitro diagnostics industry; it is ... The growth is driven by the ongoing spread of ... a primary factor associated with the upsurge of opportunistic ... diagnostic; and a broader availability of immunosuppressive medicines. Although ...
(Date:8/29/2014)... Edvance360, a leading provider of eLearning ... teaching, as well as 2011 winner and six-time-finalist for ... System, announced that Brooke Education Services, Northwest Academy, Typewell, ... Advertising Bureau of Canada (IAB Canada), StarSVCS, and HMG ... delighted to welcome each new client to the growing ...
Breaking Medicine News(10 mins):Health News:Antidepressants show potential for postoperative pain 2Health News:Etymotic’s Safe Listening Earphones and Earplugs Headed For The 2014 NSC Safety Expo 2Health News:The Today Show Features ETY•Kids® Safe-Listening Earphones by Etymotic 2Health News:Infectious Disease Testing Universe Examined in New VPG Research Report Available at MarketPublishers.com 2Health News:Infectious Disease Testing Universe Examined in New VPG Research Report Available at MarketPublishers.com 3Health News:Edvance360 Continues to Experience Growth in Corporate, K-12, Health, and Non-Profit Sectors 2
... price for a 30-second advertising spot in the 2012 Super Bowl ... study suggests that, for advertisers, it may not really matter if ... But for the sake of companies forking out big bucks on ... The study by an Oregon State University researcher, which is ...
... -- Teens who think of themselves as thrill-seekers and who ... likely to drive with other teens in the car, which ... finds. And a second study of teens involved in ... distraction and risky driving behavior often played a role. ...
... HealthDay Reporter , THURSDAY, Jan. 26 (HealthDay News) -- ... provide insight into whether patients are at high risk of ... cancer. The test, which is currently available, could ... prevent the cancer from returning. There are caveats: The ...
... a "common sense" decision to start the company in a ... belt. , "We wanted to give better stroke care," said ... of Neurology at the Medical College of Georgia at Georgia ... and his colleagues were frustrated that nearly five years after ...
... By Denise Mann HealthDay Reporter , THURSDAY, Jan. ... for liver cancer among people with hepatitis B, a new study ... hepatitis B virus, is one of the main causes of liver ... have shown promise in reducing risk for cancer. Other studies have ...
... a sensitive non-invasive marker of early lung disease in young ... from Australian researchers. "We found that LCI is elevated ... airway inflammation and Pseudomonas aeruginosa," said Yvonne Belessis, MBBS, MPH, ... may not only be a marker of early CF lung ...
Cached Medicine News:Health News:Sporting event ads viewed favorably - especially if the game is close 2Health News:Teen Driver's Friends Can Be Dangerous Distraction, Studies Find 2Health News:Test Might Predict Risk of Lung Cancer's Return 2Health News:Georgia Bio honors biotech company that enables stroke care 2Health News:Georgia Bio honors biotech company that enables stroke care 3Health News:Statins May Stave Off Liver Cancer in People With Hepatitis B 2Health News:Early cystic fibrosis lung disease detected by bronchoalveolar lavage and lung clearance index 2
The Victory single- and dual-chamber rate-responsive pacemakers from St. Jude Medical are advanced-feature systems, designed to save valuable clinic time, maximize patient safety, and provide other t...
... To help cardiologists meet the ... Toshiba introduces the high performance Infinix ... solutions combine easy-to-use controls, one-touch operations, ... to optimize workflow and allow physicians ...
Cardiac 5-Axis Bi-plane: Infinix CF-i/BP...
... on the promise of Flat Panel ... outstanding image quality, at lower doses, ... small devices and structures. The new ... at lower dose than other systems ...
Medicine Products: